What does CGON do?
CG Oncology, based in Irvine, California, focuses on developing bladder-sparing therapies for bladder cancer and went public on January 25, 2024. Its key candidates include cretostimogene and BOND-003, both targeting non-muscle invasive bladder cancer.
Headquarters
California, USA